PFS Partners’s DexCom DXCM Stock Holding History

PFS Partners’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-44	Closed	-$4.11K	–	470
2023 Q3	$4.11K	Hold	44	–	–	﹤0.01%	361
2023 Q2	$5.66K	Buy	+44	New	+$5.32K	﹤0.01%	333

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PFS Partners's DXCM Position: Q4 2023 in Review

PFS Partners sold out of DexCom (DXCM) in Q4 2023, closing a stake of 44 shares — an estimated $4.11K sold.

PFS Partners first reported a position in DXCM in Q2 2023 and held it in 2 quarters. The position peaked at $5.66K in Q2 2023. 974 funds tracked by Wall St. Rank hold DXCM as of Q4 2023.

PFS Partners reported no remaining DexCom position as of Q4 2023 after selling out during the quarter.
PFS Partners sold 44 DexCom shares in Q4 2023, an estimated $4.11K.
PFS Partners first reported a position in DexCom in Q2 2023 and held it in 2 quarters.
PFS Partners's DexCom position peaked at $5.66K in Q2 2023.
974 funds tracked by Wall St. Rank held DexCom as of Q4 2023.

Based on PFS Partners's 13F filing for Q4 2023, filed 29 Jan 2024.